Actively Recruiting
Phase 1 Randomized Trial of Subcutaneous Exl-111 and Omalizumab Versus Placebo in Healthy Adults to Evaluate Safety and Dose
Led by Excellergy Inc. · Updated on 2026-09-22
70
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating Exl-111, a drug administered by subcutaneous injection, in a Phase 1 randomized, double-blind, placebo-controlled trial with healthy adult participants aged 18 to 55 years. The study aims to find suitable doses of Exl-111 for further research by assessing safety, tolerability, and pharmacokinetics. The trial includes two parts single ascending dose SAD and multiple ascending dose MAD, with an active comparator omalizumab included in MAD. In Part A SAD, participants receive a single subcutaneous dose of Exl-111 or placebo and stay in the clinic through Day 5, followed by multiple follow-up visits until Day 141 Week 20 or end of study. Part B MAD may start after safety review of Part A data and involves up to four doses of Exl-111, placebo, or omalizumab given every 4 weeks. Participants remain in the clinic for dose administrations and return for follow-up visits until Day 196 Week 28. Participants will undergo safety monitoring, including assessment of treatment-emergent adverse events and serious adverse events from the first dose through Day 196. Pharmacokinetic evaluations will measure drug concentration and behavior in the body. The study involves clinic visits for dosing, monitoring, skin prick tests, laboratory tests, and other assessments to track safety and drug effects over approximately 28 weeks from first dose.
CONDITIONS
Brief Title
A Study to Find a Suitable Dose of Exl-111 for Further Research
Research Team
R
Reza Pishva
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here